It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release
The mean annual eGFR slope, which measures how quickly kidney function declines over time, was 1.16 mL/min/1.73m2 per year less steep in the semaglutide group
About this article Cite this article del Carmen, G.A., Patel, D., Vu, N
For best results, use consistently for at least 3 months
But to me that feels risky
Before Anyone Considers GLP-3: Key Realities Even if the hype is big, the realities are bigger: Results take time the most dramatic changes appear around 48 weeks Clinical supervision is 100% necessary Counterfeit and low-purity peptides are already circulating Long-term effects are unknown Legal risks are real Retatrutide might be the strongest metabolic peptide weve seen to date, but it is still experimental